Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company that leverages synthetic biology technology to develop and manufacture recombinant biologic drugs, enzymes, protein hormones, and antibodies. Its key products include KJ017, a recombinant human hyaluronidase; KJ103, a recombinant IgG-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone fusion protein; BJ044, a recombinant ulinastatin; BJ007, a subcutaneous ceftriaxone sodium for bacterial infections; and KJ101, a recombinant human chymotrypsin. The company operates GMP-compliant manufacturing facilities and supports a pipeline addressing areas such as infertility, Guillain-Barré syndrome, renal transplant desensitization, burns, and neoplasms through recombinant proteins, peptides, and enzymes. Shanghai Bao Pharmaceuticals markets its offerings under the Bao Pharma brand, focusing on therapeutic advancements in immunology, infectious diseases, endocrinology, and oncology. Founded in 2019 and headquartered in Shanghai, China, it plays a vital role in advancing bioprocessing and drug design platforms for innovative biologics in the pharmaceutical sector.